VJHemOnc Podcast
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets
Jan 18, 2024
Experts discuss the challenges of sequencing BCMA therapies in multiple myeloma, the prognostic value of circulating tumor cells, and the growing role of quadruplet therapies. They explore optimal combinations and sequencing, the Perseus trial comparing DARA VRD and VRD treatments, and the use of Dara KRD for newly diagnosed myeloma patients.
18:18
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Starting with bi-specific anti-BCMA therapy after CAR T cells may be more effective than starting with bi-specific antibodies and then CAR T cells in multiple myeloma.
- Circulating tumor cells (CTCs) have significant prognostic value in multiple myeloma and can provide real-time information on tumor burden, dissemination, and proliferation, making them a valuable biomarker to include in routine staging for newly diagnosed active myeloma patients.
Deep dives
Sequencing BCMA targeting therapies in multiple myeloma
The speaker discusses the challenges of sequencing different options for BCMA targeting therapies in multiple myeloma. Patient preference plays a significant role, as some prefer CAR T cells, but their availability and timely infusion may be an issue. Observational data suggests that starting with bi-specific anti-BCMA after CAR T cells may be more effective compared to starting with bi-specific antibodies and then CAR T cells. The complexity increases when considering other targets and additional therapies, but with wider availability and more experience, a clearer understanding of sequencing and combinations may emerge.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
